Neurologic and Psychological Outcomes 2 Years After Multisystem Inflammatory Syndrome in Children
- PMID: 40455448
- PMCID: PMC12131094
- DOI: 10.1001/jamanetworkopen.2025.12487
Neurologic and Psychological Outcomes 2 Years After Multisystem Inflammatory Syndrome in Children
Abstract
Importance: Neurologic and psychological sequelae are observed 1 year after hospitalization for multisystem inflammatory syndrome in children (MIS-C), but whether these concerns persist is not known.
Objective: To examine the trajectory of neurologic, psychological, and quality-of-life sequelae up to 2 years after MIS-C.
Design, setting, and participants: This longitudinal cohort study assessed children diagnosed with MIS-C from August 1, 2020, to August 31, 2021, and matched sibling and community controls, when available. The study was conducted 6 to 12 months and 18 to 24 months after discharge from a US or Canadian hospital. Data analysis was performed from May 2024 to January 2025.
Exposure: Hospitalization for MIS-C.
Main outcomes and measures: A central study site remotely administered a structured interview, surveys, neuropsychological assessment, and neurologic examination. Group differences were assessed using generalized estimating equations, accounting for matching. Variables extracted from hospital records included intensive care unit admission and echocardiographic left ventricular ejection fraction (LVEF).
Results: Overall, 95 participants were included in the study; 93 of 108 participants (86%) returned from the year 1 study and 2 participants were added in year 2 (median [IQR] age, 12.6 [11.0-15.7] years; 38 [40%] female and 57 [60%] male). Fifty-nine patients with MIS-C (mean [SD] age, 13.2 [4.0] years; 39 [66%] male) and 36 controls (mean [SD] age, 13.5 [3.5] years; 18 [50%] male) enrolled. In year 2, the MIS-C group was similar to controls on all outcome measures, except they had more somatization symptoms (Behavior Assessment Scale for Children, Third Edition mean [SD] somatization score, 52.1 [13.0] vs 46.5 [8.5]; mean difference, 5.2; 95% CI, 1.3-9.1). Within the MIS-C group, scores generally improved between initial and follow-up evaluations, a finding that was not observed in controls. Eight of 13 children with MIS-C (62%) who had abnormal neurologic examination findings in year 1 had normal examination findings by year 2. Among patients with MIS-C, measures of higher illness severity during hospitalization were associated with worse executive function in year 2 (National Institutes of Health [NIH] List Sort Working Memory Test score, -7.3 points per intensive care unit admission vs not [95% CI, -14.3 to -0.3 points] and -5.8 points per LVEF category change [95% CI, -9.1 to -2.6 points]; verbal fluency switching score, -0.8 points per LVEF category change [95% CI, -1.5 to -0.1 points]).
Conclusions and relevance: In this longitudinal, matched cohort study of children with MIS-C and controls followed up sequentially up to 2 years after hospital discharge, children with MIS-C had more somatic symptoms than control children. Overall, however, patients with MIS-C had improved neurologic and psychological outcomes between the testing intervals, performing similarly to controls on most measures by year 2 follow-up. These findings suggest that these concerns may improve over time.
Conflict of interest statement
Figures

Comment in
- doi: 10.1001/jamanetworkopen.2025.12495
Similar articles
-
Neurological and Psychological Sequelae Associated With Multisystem Inflammatory Syndrome in Children.JAMA Netw Open. 2023 Jul 3;6(7):e2324369. doi: 10.1001/jamanetworkopen.2023.24369. JAMA Netw Open. 2023. PMID: 37466939 Free PMC article.
-
Severe Pediatric Neurological Manifestations With SARS-CoV-2 or MIS-C Hospitalization and New Morbidity.JAMA Netw Open. 2024 Jun 3;7(6):e2414122. doi: 10.1001/jamanetworkopen.2024.14122. JAMA Netw Open. 2024. PMID: 38857050 Free PMC article.
-
Changes in Distribution of Severe Neurologic Involvement in US Pediatric Inpatients With COVID-19 or Multisystem Inflammatory Syndrome in Children in 2021 vs 2020.JAMA Neurol. 2023 Jan 1;80(1):91-98. doi: 10.1001/jamaneurol.2022.3881. JAMA Neurol. 2023. PMID: 36342679 Free PMC article.
-
In-hospital unfavorable outcomes of MIS-C during 2020-2022: a systematic review.Eur J Pediatr. 2024 Dec;183(12):5071-5084. doi: 10.1007/s00431-024-05787-x. Epub 2024 Oct 1. Eur J Pediatr. 2024. PMID: 39349752
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
References
-
- Dufort EM, Koumans EH, Chow EJ, et al. ; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team . Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756 - DOI - PMC - PubMed
-
- LaRovere KL, Poussaint TY, Young CC, et al. ; Overcoming COVID-19 Investigators . Changes in distribution of severe neurologic involvement in US pediatric inpatients with COVID-19 or multisystem inflammatory syndrome in children in 2021 vs 2020. JAMA Neurol. 2023;80(1):91-98. doi:10.1001/jamaneurol.2022.3881 - DOI - PMC - PubMed
-
- LaRovere KL, Riggs BJ, Poussaint TY, et al. ; Overcoming COVID-19 Investigators . Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021;78(5):536-547. doi:10.1001/jamaneurol.2021.0504 - DOI - PMC - PubMed
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical